lifethreaten
rna
virus
emerg
regularli
often
unpredict
manner
yet
drug
avail
known
rna
virus
sometim
requir
decad
research
develop
gener
prepared
outbreak
yet
unknown
virus
vizier
viral
enzym
involv
replic
http
wwwviziereuropeorg
project
setup
develop
scientif
foundat
counter
challeng
societi
vizier
studi
conserv
viral
enzym
replic
machineri
replicas
select
list
virus
order
comprehens
cover
divers
rna
viru
univers
gener
critic
knowledg
could
effici
util
jumpstart
research
emerg
rna
viru
vizier
multidisciplinari
project
involv
bioinformat
defin
function
domain
ii
viral
genom
increas
number
character
viral
genom
prepar
defin
target
iii
proteom
express
purifi
character
target
iv
structur
biolog
solv
crystal
structur
v
prelead
discoveri
propos
activ
scaffold
antivir
molecul
constitut
attract
target
drugdesign
aim
vizier
determin
mani
replicas
crystal
structur
possibl
care
introduct
sinc
discoveri
deadli
ebola
viru
filoviru
seri
previous
unknown
pathogen
emerg
virus
discov
greater
human
commun
mobil
contribut
awar
spread
respect
world
health
organ
estim
human
immunodefici
viru
hiv
sinc
discoveri
kill
million
peopl
million
peopl
today
infect
viru
unknown
lethal
hantaviru
sin
nombr
viru
emerg
western
usa
shortli
thereaft
two
unknown
paramyxovirus
caus
lethal
diseas
emerg
nipah
viru
malaysia
hendra
viru
australia
human
coronavirus
known
caus
mild
upper
respiratori
tract
infect
howev
sever
acut
respiratori
syndrom
coronaviru
sar
cov
appear
highli
pathogen
high
fatal
rate
avian
influenza
viru
strain
first
isol
human
hong
kong
caus
sinc
casualti
well
avian
influenza
virus
potenti
develop
either
genet
drift
recombin
influenza
viru
strain
virus
highli
pathogen
human
potenti
caus
pandem
sever
virus
recent
year
wide
expand
territori
caus
death
increas
number
peopl
one
exampl
west
nile
flaviviru
introduc
usa
sinc
becom
endem
entir
usa
part
canada
extens
latin
america
period
chikungunya
alphaviru
result
case
island
indian
ocean
probabl
million
case
india
current
sweep
larg
part
southeast
asia
central
africa
recent
itali
sinc
number
peopl
infect
dengu
viru
flaviviru
dramat
increas
surveil
network
report
dengu
endem
countri
dengu
case
report
dengueinfest
countri
million
report
case
estim
million
actual
casesyear
basi
larg
nonexhaust
list
evid
almost
newli
emerg
human
pathogen
virus
belong
group
rna
virus
rnadepend
rna
polymeras
rna
virus
proofread
capabl
consequ
virus
high
mutat
rate
averag
one
mutationvirusrepl
cycl
allow
fast
adapt
new
host
environ
anoth
remark
observ
almost
emerg
viral
infect
zoonot
natur
natur
host
ebola
hiv
nipah
hendra
sar
sin
nombr
anim
bat
monkey
bird
often
strong
pathogen
effect
enorm
number
yet
undiscov
virus
exist
vertebr
one
state
high
degre
certainti
novel
sometim
highli
lethal
rna
virus
emerg
futur
larg
natur
genet
pool
human
activ
deforest
intern
travel
well
result
climat
chang
may
facilit
emerg
virus
rna
virus
known
pathogen
man
may
emerg
region
yet
present
examplifi
dengu
viru
recent
year
addit
chang
fragil
balanc
specif
ecolog
nich
may
favour
emerg
novel
pathogen
agent
fear
influenza
might
develop
epidem
like
fuell
global
effort
prepar
futur
pandem
human
popul
billion
peopl
must
also
prepar
inevit
emerg
new
highli
contagi
lethal
viral
infect
origin
introduct
hiv
ebola
viru
sin
nombr
viru
nipah
hendra
sar
cov
mani
novel
virus
human
popul
could
predict
likewis
today
unabl
predict
viru
may
emerg
tomorrow
prepared
meet
threat
emerg
viru
includ
abil
rapidli
character
viru
abl
take
necessari
measur
control
latter
may
includ
vector
control
develop
vaccin
well
develop
select
antivir
drug
former
two
strategi
appropri
threat
recognis
ie
effect
prevent
infect
whilst
latter
essenti
quick
respons
unknown
threat
today
antivir
drug
avail
treatment
infect
herpesvirus
hepat
b
c
virus
hiv
influenza
virus
addit
ribavirin
approv
shown
clinic
benefit
treatment
lassa
viru
infect
specif
therapi
avail
treatment
viral
infect
fact
crucial
statement
made
drug
avail
virus
requir
decad
scientif
effort
academ
industri
sector
develop
start
decad
anticip
research
alreadi
place
whenev
next
viral
challeng
come
rna
virus
fundament
insight
potenti
molecular
target
therapi
lack
sar
coronaviru
sarscov
identifi
caus
agent
sar
epidem
research
anticoronaviru
drug
infanc
knowledg
avail
select
inhibit
replic
coronaviru
sinc
mani
import
advanc
made
although
search
antivir
sarscov
yet
produc
drug
approv
human
treatment
sadli
one
state
near
certainti
antivir
drug
avail
treatment
infect
next
newli
emerg
viru
let
us
examin
concept
hiv
drug
avail
anoth
deadli
retroviru
emerg
would
two
decad
hiv
research
make
big
differ
answer
obviou
becam
quickli
appar
structur
genom
project
adapt
panvir
approach
could
use
develop
anticip
concept
spine
structur
proteom
europ
eu
integr
project
coordin
di
stuart
oxford
uk
prototyp
largescal
european
structur
proteom
project
launch
european
union
amongst
eukaryot
target
spine
contain
one
workpackag
dedic
viral
protein
time
frustrat
virologist
face
largescal
genom
project
origin
small
genom
size
virus
obviou
virus
herpesvirida
poxvirida
could
present
respect
target
true
innov
howev
came
proposit
studi
larg
famili
relat
virus
could
fact
address
wellknown
problem
poor
crystal
success
rate
exampl
structur
first
flaviviru
polymeras
even
obscur
viru
would
immedi
impact
whole
flaviviru
field
addit
molecular
replac
techniqu
would
consider
speed
structur
solut
medic
import
flaviviru
polymeras
crystal
becam
avail
also
hope
galleri
structur
similar
virus
would
uncov
small
yetunknown
differ
could
translat
larger
vivo
differ
impact
exampl
pathogen
properti
host
rang
mechanist
peculiar
fact
approach
met
partial
success
rna
virus
main
difficulti
origin
shortag
properli
defin
viral
target
word
time
bit
ambiti
start
structur
proteom
without
address
viral
genom
vizier
start
european
integr
project
octob
million
budget
specif
address
limit
provid
comprehens
structur
character
divers
set
rna
virus
meantim
part
effort
spine
project
devot
method
develop
technic
progress
implement
individu
laboratori
combin
studi
publish
special
issu
acta
crystallogaphica
section
volum
part
octob
provid
strateg
inform
need
set
pipelin
adapt
structur
function
genom
viral
protein
involv
replic
overal
vizier
organ
shown
fig
bioinformat
virolog
repres
genom
core
name
data
gather
analysi
protein
productioncrystal
facil
repres
structur
genom
aspect
valid
section
aim
discov
novel
enzym
activ
well
potenti
lead
compound
drug
discoveri
character
close
collabor
section
project
flow
inform
materi
activ
depict
fig
thu
vizier
organ
pipelin
contain
six
themat
section
rna
virus
commonli
produc
replic
protein
larg
molecular
weight
polyprotein
may
autocatalyt
process
matur
product
size
complex
fig
pipelin
organ
vizier
project
core
larg
symbol
satellit
lab
smaller
symbol
repres
number
number
correspond
az
author
laboratori
address
respect
organ
product
crystal
recombin
fulllength
viral
protein
notori
difficult
usual
associ
low
express
level
protein
degrad
andor
insolubl
ensur
high
success
rate
product
purif
crystal
step
express
domain
individu
well
combin
domain
adopt
main
vizier
strategi
success
reli
reliabl
dissect
domain
organ
viral
polyprotein
accomplish
use
two
complementari
approach
util
respect
virali
viru
align
suit
gorbalenya
et
al
unpublish
vazymolo
viral
enzym
modular
organ
ferron
et
al
softwar
platform
develop
advanc
research
lumcmsu
virali
afmb
vazymolo
partner
vizier
consortium
commun
platform
dedic
web
server
virali
provid
stateoftheart
multimodular
environ
expert
analysi
rna
viru
genom
use
multipl
align
phylogenet
analysi
recent
studi
origin
evolut
polioviru
jiang
et
al
good
exampl
use
delin
larg
varieti
domain
also
includ
function
poorli
character
hard
express
solubl
form
vazymolo
platform
allow
vizier
partner
make
refin
domain
predict
use
differ
bioinformat
tool
blast
hca
plot
etc
access
inform
previous
made
predict
use
old
new
rna
viru
sequenc
interest
compar
crystal
success
rate
domain
predict
use
virali
vazymolo
domain
design
convert
polymeras
chain
reaction
pcr
product
section
partner
submit
target
process
inform
target
process
clone
protein
purif
store
updat
central
vizier
target
relat
databas
http
wwwviziereuropeorg
web
site
also
host
public
domain
contain
gener
data
rna
virus
structur
inform
progress
structur
solut
store
adapt
version
xtrack
harri
jone
function
aspect
eg
protocol
list
antivir
compound
store
databas
call
drugbas
leuven
although
databas
maintain
differ
place
leiden
marseil
uppsala
leuven
link
vizier
websit
vizier
user
request
technic
data
step
process
target
main
lesson
learnt
spine
project
difficulti
feed
product
pipelin
suffici
number
rna
viru
isol
incred
discrep
also
observ
publish
viral
sequenc
actual
sequenc
produc
viral
protein
cruel
fact
mani
virolog
laboratori
work
virus
differ
appreci
sequenc
nativ
isol
likewis
larg
viru
famili
complet
genom
sequenc
quit
fragmentari
see
flaviviru
exampl
consequ
vizier
first
viral
genom
program
upon
structur
genom
earli
lead
discoveri
work
superimpos
virolog
section
involv
genom
part
project
implement
viral
growth
viru
storag
appropri
biosafeti
level
condit
ii
sequenc
viral
genom
deposit
sequenc
public
databas
iii
analyz
sequenc
data
purpos
viru
identif
well
evolutionphylogeni
studi
attempt
made
collect
central
biolog
materi
danger
virus
cultiv
appropri
safeti
condit
laboratori
alreadi
experienc
task
initi
task
section
span
virus
ambiti
goal
requir
design
protocol
adapt
largescal
genom
sequenc
emonet
et
al
procedur
gener
long
cdna
enabl
easi
subsequ
onestep
amplif
domain
design
section
protein
domain
express
pcr
product
gener
clone
express
plasmid
compat
sever
express
system
without
need
subsequ
reclon
step
invitrogen
andor
popin
seri
berrow
et
al
construct
fuse
hexahistidin
tag
first
test
robust
e
coli
express
screen
set
accord
lesson
learnt
spine
project
marseil
oxford
laboratori
alzari
et
al
protein
express
solubl
fraction
purifi
twostag
purif
protocol
immobil
metal
affin
chromatographi
follow
size
exclus
chromatographi
autom
fast
protein
liquid
chromatographi
system
xpress
ge
healthcar
order
recov
pure
protein
suitabl
initi
crystal
screen
protein
character
express
e
coli
fail
addit
strategi
appli
platform
also
avail
express
mammalian
insect
cell
oxford
group
semliki
forest
viru
lausann
group
hassain
et
al
anoth
one
devot
use
delet
librari
stockholm
group
cornvik
et
al
provid
solubl
protein
also
new
domain
design
concept
section
initi
includ
preliminari
crystal
screen
due
protein
instabl
protein
transit
crystal
effort
practic
carri
partner
involv
structur
determin
crystal
product
increasingli
rescu
strategi
high
valu
target
perform
section
laboratori
implement
standard
protocol
autom
platform
guarante
reproduc
result
requir
less
protein
compar
classic
manual
crystallogenesi
sulzenbach
et
al
fogg
et
al
crystal
expos
xray
esrf
grenobl
embl
desi
hamburg
data
collect
crystal
structur
solv
convent
techniqu
heavi
atom
derivatis
usual
involv
product
selenomethionin
contain
protein
molecular
replac
appropri
second
step
cocrystal
experi
perform
put
bind
molecul
accord
function
data
provid
section
laboratori
section
design
accord
lab
without
wall
concept
crystal
structur
data
share
order
promot
synergi
partner
synergi
also
involv
global
phase
inc
develop
distribut
betavers
crystallograph
softwar
use
difficult
structur
structur
solv
one
viru
famili
group
consortium
use
experiment
data
exampl
domain
design
crystal
procedur
possibl
bind
partner
speed
structur
solut
homologu
take
one
exampl
larg
number
flaviviru
methyltransferas
solv
basi
structur
data
provid
dengu
viru
construct
egloff
et
al
structur
reveal
unfold
ctermin
domain
also
appear
cleav
produc
fulllength
protein
tbe
flaviviru
data
suggest
least
two
construct
test
flaviviru
methyltransferas
without
flexibl
ctermin
domain
strategi
valid
sinc
meaban
viru
domain
solv
smaller
construct
wherea
yokos
viru
one
solv
larger
mastrangelo
et
al
moreov
substrat
provid
section
activ
luzhkov
et
al
peyran
et
al
avail
cocrystal
experi
flaviviru
methyltransferas
construct
also
import
note
compound
screen
dengu
methyltransferas
structur
silico
may
also
suitabl
evalu
rel
effici
viral
methyltransferas
flaviviru
one
valid
section
aim
deciph
function
aspect
purifi
domain
predict
function
first
test
vitro
differ
special
platform
rnadepend
rna
polymeras
marseil
dresden
proteas
lubeck
dresden
cap
enzym
marseil
helicas
dresden
milano
put
function
avail
target
protein
first
gener
screen
perform
rna
nucleotid
bind
refin
correspond
platform
enzym
well
character
compound
drugbas
test
vitro
inhibit
assay
cellulo
evalu
effect
replic
system
revers
process
data
mine
old
activ
compound
gener
ligand
either
interest
antivir
properti
novel
infect
cell
system
use
crystallograph
studi
commonli
held
view
inhibitor
bind
partner
protein
help
crystal
stabil
protein
vedadi
et
al
dissemin
knowledg
gener
within
vizier
project
one
mission
encourag
valu
european
commiss
differ
tool
workshop
intern
congress
promot
video
websit
use
distribut
inform
vizier
project
rapidli
gener
need
intraand
extraconsortium
vehicl
aim
optim
dataresult
share
commun
gener
public
also
great
import
given
relev
project
human
health
need
justifi
use
public
money
video
describ
vizier
target
gener
public
avail
onlin
longer
version
avail
section
head
upon
request
open
access
part
websit
radic
redesign
address
increas
public
awar
interest
emerg
virus
access
easi
septemb
site
third
posit
vizier
use
request
googl
search
engin
franc
site
visit
person
day
differ
link
organ
around
rna
virus
viral
diseas
specif
agreement
sign
enabl
display
inform
detail
topic
inform
found
concern
vizier
ongo
research
within
vizier
wider
commun
virologist
vizier
websit
provid
two
type
protect
access
first
one
provid
access
technic
data
share
vizier
scientist
second
one
entri
vizier
industri
platform
vip
vip
creat
project
promot
industri
sector
allow
member
vip
access
potenti
commerci
exploit
product
consortium
research
vip
access
compani
membership
agreement
consortium
member
privileg
access
inform
knowhow
materi
techniqu
well
unpublish
scientif
result
uniqu
fundament
featur
vip
facilit
contractu
procedur
potenti
member
vizier
laboratori
agreement
sign
within
consortium
deleg
desir
first
negoti
step
vip
manag
intellectu
properti
rule
establish
agre
upon
vizier
partner
partner
decid
patent
discoveri
procedur
partit
royalti
partner
partit
owner
organ
vip
manag
togeth
differ
technolog
transfer
depart
institut
involv
patent
procedur
overal
object
vip
produc
condit
activ
collabor
vizier
scientist
corpor
world
also
increas
facilit
collabor
industri
sector
even
possibl
extend
beyond
fund
period
certain
aspect
project
gener
addit
fund
flavivirus
serv
interest
testcas
function
domain
approach
crystal
structur
dengu
viru
ntermin
methyltransferas
mtase
domain
protein
determin
shown
function
egloff
et
al
complementari
ctermin
rnadepend
rna
polymeras
rdrp
domain
subsequ
shown
function
well
given
inform
coupl
larg
number
human
pathogen
within
genu
thu
surpris
flavivirus
earli
target
vizier
project
progress
within
import
viral
genu
illustr
excit
merg
tradit
virolog
genom
structur
function
proteom
describ
fig
vizier
contribut
sequenc
flavivirus
amongst
ngoy
viru
previous
total
unknown
grard
et
al
ten
rdrp
nineteen
mtase
nine
helicas
four
proteas
produc
purifi
lead
far
thirteen
new
structur
feasibl
molecular
replac
techniqu
allow
remark
acceler
structur
phylum
coverag
also
foster
collabor
project
partner
structur
solut
west
nile
viru
polymeras
domain
speededup
dengu
viru
domain
obviou
atom
coordin
much
like
mtase
domain
remain
use
whole
flaviviru
genu
due
earli
structur
determin
flaviviru
mtase
domain
use
perform
virtual
screen
studi
aim
find
inhibitor
luzhkov
et
al
virtual
highthroughput
screen
focus
sadenosyllmethionin
sam
methyl
donor
methyltransf
bind
site
base
structur
dengu
viru
mtase
domain
dv
complex
gtp
analog
sadenosylhomocystein
sah
shown
fig
egloff
et
al
procedur
start
pharmacophor
similar
search
databas
million
commerci
avail
compound
dock
set
select
ligand
toprank
compound
repres
differ
scaffold
purchas
inhibitori
activ
test
recombin
dv
use
cap
rna
grard
et
al
figur
prepar
gilda
grard
de
viru
emerg
marseil
substrat
gpppac
measur
methyltransferas
activ
final
identifi
novel
inhibitor
previous
unknown
scaffold
see
fig
show
moder
inhibitori
activ
see
fig
addit
anoth
sah
analog
sinefungin
identifi
potent
inhibitor
submicromolar
rang
sah
analog
prove
moder
inhibitor
unpublish
result
although
cap
might
primari
target
singl
rna
cap
event
replic
flaviviru
genom
compound
deserv
attent
sinc
could
combin
antivir
molecul
rdrp
domain
good
exampl
viral
structur
genom
approach
sever
flaviviru
gene
mtase
ntermin
domain
remov
largest
part
challeng
find
solubl
rdrp
domain
construct
enzymat
activ
would
crystal
easili
construct
design
singl
aa
enzymat
activ
one
could
crystal
diffract
resolut
unfortun
allow
phase
determin
either
use
selenomethioninesubstitut
protein
convent
heavi
atom
method
anoth
construct
aa
gave
crystal
inact
enzym
whose
structur
solv
use
model
solv
origin
enzymat
activ
protein
construct
length
later
coordin
made
avail
lescar
group
expedit
crystal
structur
solut
dengu
viru
rdrp
domain
complex
nucleotid
resolut
yap
et
al
fulli
anticip
two
first
flaviviru
polymeras
structur
speed
crystal
structur
solut
flaviviru
polymeras
hemorrhag
virus
could
remov
categori
neglect
deadli
pathogen
led
novarti
institut
tropic
diseas
nitd
singapor
current
activ
research
programm
merg
highthroughput
screen
result
ie
hit
crystal
soak
experi
order
drive
forward
structurebas
drugdesign
effort
flaviviru
rdrp
first
flaviviru
helicas
crystal
structur
yellow
fever
viru
determin
wu
et
al
turn
structur
consider
help
aim
vizier
consortium
cover
structur
encompass
genom
tree
flaviviru
genu
structur
west
nile
kunjin
mastrangelo
et
al
kokobera
de
colibu
et
al
murray
valley
enceph
viru
mancini
et
al
unpublish
helicas
recent
determin
summari
result
make
structurebas
drugdesign
inhibitor
possibl
four
enzymat
activ
carri
flaviviru
protein
address
vizier
project
viral
structur
genom
look
excit
crystallograph
earli
stage
studi
given
viru
famili
structur
data
yet
exist
hunger
novel
structur
often
contradict
crystal
structur
determin
mani
similar
structur
exampl
use
molecular
replac
techniqu
insid
given
viru
famili
imper
realiz
even
vizier
contribut
mani
origin
fold
yet
potenti
disenchant
part
structur
biologist
share
virologist
forese
connect
longknown
virusspecif
data
eg
host
rang
specif
diseas
specif
geograph
distribut
name
new
structur
data
realiz
understand
system
biolog
implic
applic
hostpathogen
interact
besid
obviou
desir
prepar
tackl
emerg
diseas
inform
content
larg
number
crystal
structur
within
viru
famili
current
estim
likewis
anticip
crystal
structur
complex
replicas
substrat
perhap
importantli
protein
partner
sure
benefit
wealth
structur
determin
within
vizier
project
elsewher
start
flaviviru
polymeras
project
possibl
predict
flaviviru
polymeras
domain
would
yield
crystal
structur
difficulti
appli
flaviviru
complex
avail
mani
helicas
polymeras
structur
like
speed
excit
crystallograph
work
complex
possibl
homolog
domain
differ
viru
famili
differ
function
macrodomain
x
domain
may
exampl
addit
archa
eukarya
prokarya
domain
present
coronavirus
alphavirus
rubella
viru
hepat
e
viru
howev
sinc
associ
phosphatas
activ
ribosebind
activ
differ
phyla
priori
consid
function
would
remain
conserv
crystal
structur
macrodomain
coupl
function
studi
eg
undoubtedli
help
find
new
unexpect
function
across
differ
viru
famili
tackl
sever
target
parallel
may
provid
research
incent
virus
present
unaddress
drugdesign
commun
project
month
result
viral
cdna
introduc
protein
product
pipelin
result
origin
solv
apoand
binarycomplex
crystal
structur
alphavirus
rhabdovirus
calicivirus
coronavirus
reovirus
picornavirus
full
account
report
elsewher
latter
genu
simultan
structur
determin
coxsacki
polymeras
jabafi
et
al
gruez
et
al
unpublish
proteas
hilgenfeld
et
al
unpublish
discoveri
potent
inhibitor
put
helicas
de
palma
et
al
unpublish
provid
uniqu
opportun
compar
evalu
efficaci
target
differ
compon
replicon
perhap
simultan
develop
lead
potent
drug
combin
may
well
data
translat
polioviru
field
antivir
molecul
may
help
complet
erad
campaign
final
vizier
project
first
step
toward
integr
studi
viral
replicas
cellular
context
unravel
complex
interactom
exist
around
viral
replicas
benefit
structur
data
allow
futur
system
biolog
approach
detail
structur
function
tempor
interact
studi
replicas
ligand
substrat
viralcellular
partner
undoubtedli
extend
knowledg
beyond
antivir
field
